A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
A phase 1/2 trial of Olaparib and Bevacizumab in ovarian cancer, small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT02734004 by AstraZeneca, with 264 participants enrolled, started 2016-03-17 and due to reach its primary completion in 2021-09-17. Interventions recorded: Olaparib, MEDI4736 and Bevacizumab. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Shares Olaparib, AstraZeneca, Ovarian cancer and the tag pipeline.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Bevacizumab, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialIxovex-1 Single Agent and Combination Therapy
Shares IQVIA and the tag pipeline.
- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, AstraZeneca and the tag pipeline.
- TrialA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Olaparib, AstraZeneca and the tag pipeline.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Olaparib, AstraZeneca and the tag pipeline.